Two late‑stage atopic dermatitis programs reported data that investors and clinicians judged noteworthy. Evommune reported positive phase 2a results for EVO301, an IL‑18 fusion protein, achieving statistically significant EASI improvements versus placebo at Week 12 and triggering a large premarket stock rally. William Blair analysts noted the competitive placebo‑adjusted reductions relative to marketed biologics. Separately, Nektar disclosed one‑year maintenance data for rezpegaldesleukin showing durable and deepening skin clearances at 52 weeks for monthly and quarterly dosing. Nektar’s CMO compared competitive efficacy and dosing frequency favorably against established agents. Both readouts sharpen the competitive landscape for long‑acting biologics in moderate‑to‑severe atopic dermatitis and will shape development and positioning decisions.